1. Clinical Staphylococcus aureus inhibits human T-cell activity through interaction with the PD-1 receptor.
- Author
-
Mellergaard M, Skovbakke SL, Jepsen SD, Panagiotopoulou N, Hansen ABR, Tian W, Lund A, Høgh RI, Møller SH, Guérillot R, Hayes AS, Erikstrup LT, Andresen L, Peleg AY, Larsen AR, Stinear TP, Handberg A, Erikstrup C, Howden BP, Goletz S, Frees D, and Skov S
- Subjects
- Humans, Staphylococcus aureus, Programmed Cell Death 1 Receptor, T-Lymphocytes, Staphylococcal Infections microbiology, Methicillin-Resistant Staphylococcus aureus
- Abstract
Importance: Therapies that target and aid the host immune defense to repel cancer cells or invading pathogens are rapidly emerging. Antibiotic resistance is among the largest threats to human health globally. Staphylococcus aureus ( S. aureus ) is the most common bacterial infection, and it poses a challenge to the healthcare system due to its significant ability to develop resistance toward current available therapies. In long-term infections, S. aureus further adapt to avoid clearance by the host immune defense. In this study, we discover a new interaction that allows S. aureus to avoid elimination by the immune system, which likely supports its persistence in the host. Moreover, we find that blocking the specific receptor (PD-1) using antibodies significantly relieves the S. aureus -imposed inhibition. Our findings suggest that therapeutically targeting PD-1 is a possible future strategy for treating certain antibiotic-resistant staphylococcal infections., Competing Interests: The authors declare no conflict of interest.
- Published
- 2023
- Full Text
- View/download PDF